McKesson (MCK) CEO Brian Tyler Sells $6.6M of Stock

Brian Tyler, the CEO of McKesson Corporation, recently sold 8,463 shares of the company. The transaction, which took place on June 17, 2026, was part of a planned sale. Tyler sold the shares at an average price of $775.13 each, generating a total value of approximately $6.56 million.

Insider Buying and Selling at McKesson Corporation

In addition to Brian Tyler's recent sale, other insiders have also been selling shares under planned transactions. On June 9, 2026, Tyler sold another 4,929 shares at $763 each. Earlier in June, Napoleon Rutledge Jr., the Senior Vice President, Controller & CAO, sold 133 shares at $764, while Thomas Rodgers, the EVP, Chief Strategy & BDO, sold a total of 822 shares over two days at prices around $735. LeAnn Smith, EVP & Chief HR Officer, sold 1,810 shares at $735.5 on June 1, 2026.

Other Institutional Activity in McKesson Corporation

Among McKesson's institutional investors, BlackRock, Inc. reduced its holdings by 70,566 shares, ending with 11,418,384 shares valued at about $9.88 billion. Vanguard Capital Management LLC acquired 7,960,724 shares, bringing its total to the same amount, valued at $6.89 billion. State Street Corp trimmed its stake by 48,423 shares, holding 5,731,756 shares worth roughly $4.96 billion. FMR LLC increased its position by 398,301 shares to 3,603,423 shares, valued at approximately $3.12 billion, while JPMorgan Chase & Co added 679,082 shares, totaling 3,268,340 shares valued at $2.81 billion.

McKesson Corporation Stock Down 14.2%

Shares of McKesson Corporation, trading on the NYSE under the ticker MCK, were recently priced at $779.8. The company boasts a market capitalization of roughly $91.3 billion and a P/E ratio of 20.3. Its 52-week trading range has seen a low of $637 and a high of $999. McKesson's 50-day moving average stands at $792.59, while its 200-day moving average is $823.90. The company's beta is a low 0.315, indicating less volatility compared to the market.

Recent Earnings

McKesson reported revenue of $403.43 billion, reflecting a growth rate of 6%. The company's earnings per share (EPS) is $38.41, with a net margin of 1.18%. McKesson's return on equity (ROE) stands at a healthy level. The next earnings release is scheduled for August 5, 2026.

Dividend

McKesson offers an annual dividend rate of $3.28, yielding 0.42% with a payout ratio of 8.26%. This provides a modest return for income-focused investors.

Analysts Set New Price Targets

Analysts have maintained a positive outlook on McKesson. On June 10, 2026, Barclays maintained its buy rating with a target price of $925. Other firms like Citigroup and UBS also upheld their buy ratings, setting target prices at $945 and $1,050, respectively. The consensus among 15 analysts is a strong buy, with a mean target price of $941.4.

About McKesson Corporation

McKesson Corporation is a leading provider of healthcare services, distributing a wide range of pharmaceutical and medical products. Headquartered in Irving, Texas, McKesson operates through segments such as North American Pharmaceutical, Oncology & Multispecialty, and Medical-Surgical Solutions. The company delivers products to various healthcare facilities and offers a suite of technological and consulting services to improve healthcare outcomes. McKesson employs around 41,600 people and is led by CEO Michele Lau.

Bottom Line

The recent insider sales at McKesson, including CEO Brian Tyler's planned transaction, highlight ongoing executive activity. Investors keep a close eye on such moves as part of broader market analysis. McKesson's strong market position and steady revenue growth, coupled with analyst endorsements, continue to make it a stock of interest. As always, remember that 13F filings and insider transactions are backward-looking and may not reflect current positions.